Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
120 Leser
Artikel bewerten:
(0)

Cardiac Resynchronization Therapy Market Worth $5.1 Billion by 2024 - Exclusive Report by MarketsandMarkets

CHICAGO, April 17, 2019 /PRNewswire/ -- According to the new market research report "Cardiac Resynchronization Therapy Market by Product Type (Cardiac Resynchronization Therapy Defibrillator and Cardiac Resynchronization Therapy Pacemaker), End User (Hospitals & Cardiac Centers and Ambulatory Surgery Centers) - Global Forecast to 2024", published by MarketsandMarkets, the Cardiac Resynchronization Therapy (CRT) Market is projected to reach USD 5.1 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 4.4%.

MarketsandMarkets Logo

Don't miss out on business opportunities in Cardiac Resynchronization Therapy Market

The growth of the CRT systems market is mainly driven by the increasing incidence of target disease and growth in the geriatric population. Rising investments and support, along with technological advancements, are also contributing to the growth of the market.

By product type, the cardiac resynchronization therapy defibrillators (CRT-Ds) segment accounted for the largest share market in 2018

On the basis of product type, the CRT market is segmented into cardiac resynchronization therapy defibrillators (CRT-Ds) and cardiac resynchronization therapy pacemakers (CRT-Ps). The CRT-Ds segment accounted for the largest share of the market in 2018. This is majorly attributed to the increasing acceptance of CRT-Ds over pacemakers and the launch of technologically advanced devices. Furthermore, growth in this market segment is largely driven by the increasing incidence of target diseases.

Browse in-depth TOC on "Cardiac Resynchronization Therapy Market"

59 - Tables

27 - Figures

107 - Pages

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=194506584

In 2018, the hospitals & cardiac centers segment dominated the CRT market

On the basis of end user, the market is segmented into hospitals & cardiac centers and ambulatory surgery centers. Hospitals & cardiac centers accounted for the largest share of the market in 2018. The increasing prevalence of CVD, rising number of surgical procedures performed, favorable reimbursement scenario, and the increasing number of critical care and intensive care units are some of the key factors driving the growth of the hospitals & cardiac centers segment.

North America to dominate the CRT market during the forecast period

In 2018, North America dominated the CRT market, followed by Europe. Increasing incidence of CVDs, increasing healthcare expenditure, and availability of technologically advanced devices are the factors propelling the growth of the market in the region.

The Asia Pacific region is projected to register the highest growth rate in the CRT market during the forecast period. Favorable reimbursement scenario in Japan, rising geriatric population in China, rising incidence of CVDs, improving healthcare infrastructure, growing middle-class population, and rising disposable income levels in India are some of the key factors driving the growth of the market in the Asia Pacific.

Inquiry Before Buying:

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=194506584

CONMED Corporation (US), Medtronic Plc (Ireland), Olympus (Japan), Ethicon (US), Erbe Elektromedizin GmbH (Germany), KLS Martin (Germany), Stryker Corporation (US), I.C Medical (US), Symmetry Surgical Inc. (US), Utah Medical Products Inc (US), Zimmer Biomet (US), Pall Corporation (US), Ecolab (US), and Deroyal (US) are some major players in the global Smoke Evacuation System Market.

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Research Insight:

https://www.marketsandmarkets.com/ResearchInsight/cardiac-resynchronization-therapy-market.asp

Visit Our Website: https://www.marketsandmarkets.com

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.